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ABSTRACT
Glioblastoma (GBM) are characterized by increased invasion into the surrounding 
normal brain tissue. RTVP-1 is highly expressed in GBM and regulates the migration 
and invasion of glioma cells. To further study RTVP-1 effects we performed a pull-
down assay using His-tagged RTVP-1 followed by mass spectrometry and found 
that RTVP-1 was associated with the actin polymerization regulator, N-WASP. This 
association was further validated by co-immunoprecipitation and FRET analysis. We 
found that RTVP-1 increased cell spreading, migration and invasion and these effects 
were at least partly mediated by N-WASP. Another protein which was found by the 
pull-down assay to interact with RTVP-1 is hnRNPK. This protein has been recently 
reported to associate with and to inhibit the effect of N-WASP on cell spreading. 
hnRNPK decreased cell migration, spreading and invasion in glioma cells. Using co-
immunoprecipitation we validated the interactions of hnRNPK with N-WASP and RTVP-
1 in glioma cells. In addition, we found that overexpression of RTVP-1 decreased the 
association of N-WASP and hnRNPK. In summary, we report that RTVP-1 regulates 
glioma cell spreading, migration and invasion and that these effects are mediated 
via interaction with N-WASP and by interfering with the inhibitory effect of hnRNPK 
on the function of this protein.
INTRODUCTION
Glioblastomas (GBM), the most common and 
malignant primary brain tumors, are characterized by 
high proliferation, vascularization and invasion into the 
surrounding normal tissue [1-3]. The median survival 
of patients with GBM, following tumor resection and 
treatment with radiation and chemotherapy, is less than 
16 months [1, 4, 5]. The poor prognosis of GBM patients 
is attributed to the infiltrative nature of these tumors [6-8] 
and to the presence of therapy resistant residual cancer 
stem cells [9]. 
Related to testis-specific, vespid and pathogenesis 
protein 1 (RTVP-1) was cloned from human GBM cell 
lines by and was termed glioma pathogenesis-related 
protein (GLIPR1) or RTVP-1 [10, 11]. RTVP-1 contains 
a putative signal peptide, a transmembrane domain and a 
SCP domain, which is common to other homologs of this 
protein [12, 13]. Our previous studies demonstrated that 
the expression of RTVP-1 was correlated with the degree 
of malignancy of astrocytic tumors [12, 13] and that it 
was involved in the regulation of the growth, survival and 
invasion of glioma cells [12]. The expression of RTVP-1 
was recently reported to be increased in additional tumors 
including Wilm’s tumors due to its hypomethylation [14] 
and in invasive melanoma [15]. In these tumors, silencing 
of RTVP-1 resulted in reduced cell migration and 
proliferation. In contrast, RTVP-1 expression was found 
to be downregulated in prostate tumors [16]. 
RTVP-1 expression is induced in glioma cells by the 
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protein kinase C (PKC) isoforms, PKCα and PKCε, via 
phosphorylation of the transcription factor serum response 
factor (SRF) [17]. In addition, we recently identified 
RTVP-1 as a novel target of the tumor suppressor miRNA, 
mir-137, which inhibits the self-renewal of glioma stem 
cells (GSCs) and promotes their differentiation by 
targeting RTVP-1 and the CXCR4 pathway [18].
The WASP family consists of five members in 
mammalian cells, including WASP, N-WASP (neural 
WASP), WAVE1 (WASP family verprolin homologous 
protein 1), WAVE2, and WAVE3, which can be further 
divided into two subgroups, WASP/N-WASP and WAVEs 
[19]. WASP family proteins integrate multiple upstream 
signals to induce actin polymerization through the Arp2/3 
complex, an activator of actin filament nucleation and 
branching [20-22]. Several lines of evidence indicate that 
these proteins are necessary for cell protrusive activity 
associated with cell migration and invasion. Moreover, 
the expression of the WASP family proteins has been 
associated with malignant phenotypes of cancer cells, 
including glioma [23], indicating the importance of these 
proteins in cancer cell migration and invasion [24].
Although our recent studies implicated RTVP-1 as 
a tumor promoter in GBM, the mechanisms by which this 
protein induces glioma cell migration and invasion are 
not yet understood. In this study we identified N-WASP 
and hnRNPK as novel interacting proteins of RTVP-1 
and demonstrated that RTVP-1 induced cell spreading, 
migration and ECM degradation in an N-WASP dependent 
manner. Moreover, overexpression of RTVP-1 decreased 
the association of N-WASP and hnRNPK, which has been 
reported to inhibit N-WASP effects on cell spreading and 
migration.
RESULTS
RTVP-1 regulates the invasion and matrix 
degradation of glioma cells and glioma stem cells 
(GSCs)
We previously reported that the expression of 
RTVP-1 correlated with the degree of malignancy in 
astrocytic tumors and that overexpression of RTVP-1 
induced migration [17] and invasion of glioma cells [12]. 
To further examine the role of RTVP-1 in glioma 
cell invasion we overexpressed it in glioma cell lines that 
express low levels of this protein. As presented in Figure 
1A, overexpression of RTVP-1 in the A172 and U251 
cells increased cell invasion as analyzed using the Boyden 
chamber assay. We also examined the role of RTVP-
1 in the migration and invasion of GSCs, which have 
been associated with glioma cell infiltration and tumor 
recurrence [25, 26]. The preparation and characterization 
of these cells was previously reported [27]. Silencing of 
RTVP-1 in the HF2562 and HF2609 GSCs decreased 
cell invasion (Figure 1B). Similar results were previously 
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reported for silenced U87 cells [12]. 
The effect of RTVP-1 on glioma cell invasion 
was also examined by matrix degradation assay using a 
fluorescent labeled gelatin. As presented in Figure 1C, 
overexpression of RTVP-1 in the A172 and U251 cells 
significantly increased gelatin degradation as compared 
with the control vector (CV) cells (Figures 1C and 1D) 
and in accordance with the results obtained for the Boyden 
Figure 1: RTVP-1 promotes cell invasion and invadopodia formation. A172 or U251 cells were transduced with adenovirus 
vectors expressing Flag-RTVP-1 or a control vector (CV) and 48 h later RTVP-1 expression was determined by Western blot analysis and 
cell invasion was determined using a Boyden chamber/matrigel assay A. Cells were plated on the top compartment of a Boyden chamber 
and after 8 hr of incubation, cells that traversed the matrigel-coated filters were stained and counted. Similar assays were performed for 
the HF2562 and HF2609 GSCs that were transduced with lentivirus vector expressing RTVP-1 or control shRNAs B. A172 and U251 
overexpressing RTVP-1 were plated on fluorescent fibronectin/gelatin coated coverslips. Twelve hours later, the cells were fixed and 
stained for F-actin using TRITC-conjugated phalloidin. Representative degradation assay images of A172 and U251 cells are presented 
C. The percentage of matrix degradation per culture cell number was analyzed as described in the methods D. A172 cells were plated on 
fibronectin-coated plates and the presence of podosomes was identified by staining the cells with F-actin and anti-cortactin antibody E. 
The number of podosomes per field was determined as described in Methods F. Invadopodia formation in the RTVP-1 overexpressing 
A172 cells was identified by the co-localization of F-actin and cortactin as dark, non-fluorescent areas of degradation. A Confocal z-stack 
representative image shows the presence of invadopodia protrusion penetrating into the fibronectin/gelatin matrix in RTVP-1 overexpressing 
A172 cells; the degradation site localizes specifically at the area of F-actin and cortactin co-localization G. The percentage of invadopodia 
per cell number in CV and RTVP-1 overexpressing cells was determined in 8 different fields for triplicate wells for each cell type H. One 
representative of three similar experiments is presented. The results are presented as mean ± SE and represent three different experiments 
(A,B,D). *P < 0.001. 
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chamber assay. 
Matrix degradation has been associated with the 
formation of podosomes and invadopodia [28]. Podosomes 
are precursor structures that can mature on physiological 
substrates into invadopodium-type structures that exhibit 
a matrix degradation activity [29] and are identified by the 
co-localization of F-actin and cortactin [30]. To examine 
the effect of RTVP-1 on podosome formation in glioma 
cells, we employed A172 cells overexpressing RTVP-
1 (Figure 1A). Cells were plated on fibronectin-coated 
plates and podosomes were identified by staining the cells 
with F-actin and anti-cortactin antibodies. As presented 
in Figures 1E and 1F, overexpression of RTVP-1 in the 
A172 cells resulted in a strong induction of podosomes in 
these cells compared to CV cells. To analyze the effect of 
RTVP-1 overexpression on invadopodia expression, cells 
were plated on fibronectin/gelatin-GFP and were stained 
for F-Actin and cortactin. Invadopodia were identified as 
structures stained for both F-actin and cortactin that were 
also able to degrade the fluorescent matrix (Figure 1G). 
The number of the invadopodia was significantly higher 
in A172 cells overexpressing RTVP-1 as compared to CV 
cells (Figure 1H).
RTVP-1 is associated with N-WASP
To elucidate the mechanism underlying the effects 
of RTVP-1 on migration and invasion by RTVP-1 
we performed a pull-down assay using a His-tagged 
RTVP-1 in U87 glioma cell lysates followed by a mass 
spectrometry analysis (Figure 2A). We identified the key 
actin regulator protein N-WASP [31] and heterogeneous 
nuclear ribonucleoprotein K (hnRNPK) [32] as potential 
Figure 2: Interaction of RTVP-1 and N-WASP in glioma cells. His-tag affinity pull-down assay was employed as a screening 
assay for identifying RTVP-1 interacting proteins. The interacting complexes were resolved and stained for further analysis. N-WASP and 
hnRNPK were two of the pull-down complexes identified with MassSpec analysis A. Total RNA was extracted from normal brains and 
GBM specimens and the expression of N-WASP was determined using real-time PCR. Data from individual human tissues are presented 
with the median and interquartile range noted. Age adjusted t-test, P = 0.001. Results were normalized relative to the levels of S12 mRNA 
and are presented relative to a reference sample B. The expression of N-WASP was also examined in human astrocytes and glioma cell 
lines C. and in human neural stem cells (NSCs) and fifteen cultures of glioma stem cells GSCs D. using real-time PCR. U87 glioma cells 
and the HF2609 GSCs were analyzed for the association of RTVP-1 and N-WASP using reciprocal co-immunoprecipitation E. FRET 
analysis using RTVP-1 tagged to CFP and N-WASP tagged to YFP was performed. The two plasmids were co-transfected into U87 cells 
and 24 h later the cells were fixed and FRET efficiency was determined as described in the methods F. One representative of three similar 
experiments is presented. P < 0.001
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interacting proteins of RTVP-1. We first examined 
the expression of N-WASP in normal brain and GBM 
specimens and found no significant differences in the 
expression of this protein (Figure 2B). In contrast, we 
found that N-WASP expression was increased in glioma 
cell lines compared with normal human astrocytes 
(Figure 2C) and in glioma stem cells (GSCs) compared 
with neural stem cells (NSCs) (Figure 2D). We then 
analyzed the interaction of RTVP-1 with N-WASP since 
this protein plays a major role in actin polymerization and 
cell migration [33]. Using reciprocal immunoprecipitation 
analyses, we confirmed the interaction of RTVP-1 and 
N-WASP in the U87 cells and the HF2609 GSCs (Figure 
2E). To further validate this interaction we performed 
FRET analysis using RTVP-1 tagged to CFP and N-WASP 
tagged to YFP. The two plasmids were co-transfected into 
U87 cells and 24 h later the cells were fixed and FRET 
efficiency was determined as described in the methods. 
As presented in Figure 2F, RTVP-1 and N-WASP showed 
FRET efficiency of 33.43 + 2.72%, suggesting a direct 
interaction of these two proteins in glioma cells. 
N-WASP mediates RTVP-1 effects on cell 
spreading and migration of glioma cells
Cell adhesion and motility depend on the 
interactions of cells and extracellular matrix substrates. 
When plated onto matrix coated surfaces, cells first flatten 
and deform extensively as they spread [34]. Cell spreading 
is driven by actin polymerization, which is regulated by 
actin nucleation machinery involving the Arp2/3 complex 
[35] that is activated by the WASP protein family [36]. 
We next examined the effects of RTVP-1 on glioma cell 
spreading and the role of N-WASP in this process and 
found that overexpression of RTVP-1 in the A172 cells 
enhanced cell spreading (Figure 3A), whereas silencing 
of RTVP-1 in the U87 cells inhibited this process (Figure 
3B). 
We then studied the interaction of RTVP-1 and 
N-WASP in glioma cell functions. For these studies 
RTVP-1 was overexpressed in A172 cells that were 
silenced for N-WASP (Figure 3C), and cell spreading, 
migration and ECM degradation were determined. A 
decrease of ~30% was observed in the spreading of RTVP-
1 overexpressing cells that were silenced for N-WASP as 
compared to cells that were not silenced for this protein 
(Figure 3D). Similarly, silencing of N-WASP also 
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abrogated the increased cell migration (Figure 3E) and 
fibronectin/gelatin degradation induced by overexpression 
of RTVP-1 in A172 cells (Figures 3F, 3G). Thus, the 
effects of RTVP-1 on glioma cell migration, spreading and 
ECM degradation were at least partially mediated by its 
interaction with N-WASP.
hnRNPK is an interacting protein of RTVP-1 
that is downregulated in GBM and inhibits cell 
migration
Another protein that was identified as a putative 
interacting protein of RTVP-1 is hnRNPK. Inhibition of 
hnRNPK was reported to increase cell spreading [37]. 
Moreover, hnRNPK was reported to directly interact 
with N-WASP in the periphery of spreading cells and 
overexpression of hnRNPK reversed the formation of 
filopodia induced by N-WASP [33]. Since hnRNPK was 
identified as a potential interacting protein of RTVP-
1 using the pull-down assay, we first validated the 
interaction of these two proteins using reciprocal co-
immunoprecipitation in glioma cells and GSCs (Figure 
4A). We then examined the expression and function of 
hnRNPK in glioma cells. We found that hnRNPK was 
highly expressed in normal brain and its expression 
was lower in astrocytic tumors in a tumor grade manner 
and in an inverse pattern to that of RTVP-1 (Figure 
4B). Interestingly, hnRNPK expression was higher in 
oligodendroglioma compared with astrocytic tumors. 
We then examined the effects of hnRNPK on 
glioma cell spreading, migration and invasion. We found 
that overexpression of hnRNPK inhibited glioma cell 
spreading (Figure 4C) and migration (Figure 4D), whereas 
silencing of hnRNPK induced the opposite effect (Figures 
4E and 4F). Thus, hnRNPK is expressed in low levels in 
glioma and its low expression is associated with increased 
migration and invasion.
Recent studies have identified five GBM subtypes, 
which are classified based on their transcriptional 
Figure 3: The effect of RTVP-1 on glioma cell spreading and migration is mediated by N-WASP. U87 cells transfected with 
control vector or RTVP-1 A. or A172 cells were silenced for RTVP-1 B. for 3 days were examined for cell spreading. The figures are from 
one representative out of three similar experiments. The results are presented as mean ± SE and represent three different experiments (A, 
B). *p < 0.05. A172 cells overexpressing RTVP-1 were transfected with N-WASP shRNA, or with a non-specific shRNA as a transfection 
control and the expression of N-WASP was analyzed using Western blot analysis C. Spreading assays D., transwell migration E. and ECM 
degradation assay (F, G) were performed as described in the methods. One representative of three similar experiments is presented. *p < 
0.05; **p < 0.0001 
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Figure 4: hnRNPK inhibits cell migration and its interaction with RTVP-1 decreases its association with N-WASP. 
The association of RTVP-1 and hnRNPK was analyzed in U87 cells using reciprocal co-immunoprecipitation with either anti-N-WASP or 
RTVP-1 antibodies A. Total RNA was extracted from normal brains (NB) and astrocytic tumor specimens and the expression of hnRNPK 
was determined using real-time PCR B. Data from individual human tissues are presented with the median and interquartile range noted. 
Age adjusted t-test, P = 0.001. Results were normalized relative to the levels of S12 mRNA and are presented relative to a reference sample 
B. A172 cells were transfected with a vector overexpressing hnRNPK, or with a control vector (CV). Cell spreading assays C. and transwell 
migration assays D. were performed as described in the methods. U87 cells were transfected with hnRNPK siRNA or with a non-specific 
siRNA as a transfection control. Cell spreading assays E. and transwell migration assays F. were performed. The means ± S.E. from 
three independent experiments are shown as relative spreading after normalization to that in mock transfected cells. *p < 0.05. hnRNPK, 
N-WASP and RTVP-1 expression was examined in different subtypes of GBM. The gene expression plot presenting five GBM subtypes of 
496 primary GBM specimens from TCGA showing differential hnRNPK gene expression G. ANOVA F-test is presented.
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signatures into proneural, G-CIMP, neural, classical 
and mesenchymal subtypes [38, 39]. These subtypes 
have distinct differential genetic alterations, molecular 
signature and cellular phenotypes and in particular, the 
mesenchymal subtype of GBM is characterized by an 
increased level of infiltration and poor prognosis. Since 
hnRNPK inhibits cell migration in glioma cells, we 
examined its expression in the different GBM specimens. 
Using the TCGA data portal [26], we analyzed the relative 
expression of hnRNPK in the five GBM subtypes and 
found that its mean expression was significantly higher 
in tumors that are classified as the proneural and C-CIMP 
and the lowest in the mesenchymal subtypes (Figure 4G). 
In contrast, the expression of both N-WASP and RTVP-
1 was lower in the proneural GBM compared to the 
mesenchymal subtype (Figure 4G). 
RTVP-1 decreases the association of N-WASP and 
hnRNPK
The association of hnRNPK with N-WASP has been 
reported to inhibit N-WASP effects on cell spreading. We 
therefore examined if this interference occurs also in 
glioma cells. As presented in Figure 5A, overexpression 
of hnRNPK decreased the gelatin degradation of the 
U87 glioma cells, whereas overexpression of N-WASP 
induced the opposite effect. Overexpression of hnRNPK 
inhibited the ECM degradation induced by N-WASP, 
similar to its inhibitory effects on N-WASP-induced cell 
spreading [33]. Since both RTVP-1 and hnRNPK are 
associated with N-WASP but have opposite effects on cell 
spreading and ECM degradation, we hypothesized that 
RTVP-1 may interfere with the association of hnRNPK 
and N-WASP. To test this hypothesis we examined the 
association of N-WASP and hnRNPK in the presence 
or absence of RTVP-1. We found that overexpression of 
RTVP-1 significantly reduced the association of N-WASP 
and hnRNPK (Figure 5B) and abrogated the inhibitory 
effect of hnRNPK on N-WASP-induced cell migration 
when co-expressed in the A172 glioma cells (Figure 5C). 
Thus, our data indicate that N-WASP mediates some of 
RTVP-1 effects on cell spreading, migration and invasion 
and that RTVP-1 promotes N-WASP effects by decreasing 
the inhibitory impact of hnRNPK (Figure 5D).
Figure 5: RTVP-1 inhibits the interaction of N-WASP and hnRNPK in glioma cells. Fluorescent gelatin degradation assays 
were performed using cells transfected with hnRNPK, N-WASP or a combination of both A. Lysates were prepared from U87 cells (CV 
cells and RTVP-1- overexpressing cells) and immunoprecipitation was performed with anti-hnRNPK antibody. The immunoprecipitates 
(IP) and aliquots of the lysates were analyzed by Western blotting with anti- N-WASP, anti-hnRNPK, and anti-RTVP-1 antibodies B. Cell 
transwell migration assay was performed in A172 cells overexpressing N-WASP, hnRNPK and combination of both with and without 
RTVP-1 C. One representative of three similar experiments is presented. P < 0.001. A model demonstrating that N-WASP mediates some 
of RTVP-1 effects on cell spreading, migration and invasion and that RTVP-1 promotes N-WASP effects by decreasing the association of 
hnRNPK and N-WASP (Figure 5D).
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DISCUSSION
GBM represent 70% of all malignant primary 
brain tumors [1]. The infiltration of tumor cells into the 
surrounding brain tissue and the presence of treatment 
resistant GSCs are the main cause of tumor recurrence 
and poor prognosis of GBM patients [40]. In this study 
we explored the mechanisms by which RTVP-1 induced 
glioma cell migration and invasion and identified the key 
actin regulator N-WASP as a novel interacting protein and 
a mediator of RTVP-1 effects.
We found that overexpression of RTVP-1 in A172 
cells, which express low levels of this protein, induced 
cell invasion as indicated by both Boyden chamber and 
matrix degradation assays. We next examined the effect of 
silencing of RTVP-1 on the migration of GSCs, which are 
implicated in therapeutic resistance, tumor invasion and 
recurrence [38, 39] and found that silencing of RTVP-1 in 
these cells resulted in decreased migration and invasion. 
We recently identified RTVP-1 as a novel target 
of the tumor suppressor miR-137. We demonstrated that 
miR-137 was downregulated in GBM due to promoter 
hypermethylation and that miR-137 inhibited GSC self-
renewal and promoted the differentiation of these cells by 
targeting RTVP-1 which downregulated CXCR4 [18]. The 
role of RTVP-1 in GSC migration and invasion, as shown 
here, is in agreement with its function in GSC self-renewal 
and further marks RTVP-1 as an attractive therapeutic 
target for the eradication of GSCs. 
Since RTVP-1 increases cell migration and induces 
MMP-2 activity [12], we next performed fluorescent 
gelatin degradation assay and found a significant 
higher degree of degradation in response to RTVP-1 
overexpression. Recent reports demonstrated that in 
metastatic melanoma cells elevated RTVP-1 levels are 
correlated with increased invasive potential, and that 
silencing of RTVP-1 reduces cell migration, invasion and 
proliferation [15]. Thus, RTVP-1 appears to play a major 
role in tumor migration and invasion.
Invasive tumor cells extend protrusions from 
their ventral surface into the surrounding matrix, such 
as podosomes, which result in degradation of the ECM 
at discrete foci [41]. In parallel to the induction of cell 
invasion and ECM degradation by RTVP-1 we also found 
that RTVP-1 induced the formation of podosomes and 
invadopodia in glioma cells. In recent years it has become 
clear that invadopodia have an important role in the 
invasion of glioma [30], and several proteins which are 
involved in the formation of invadopodia in glioma cells 
have been further explored as potential therapeutic targets 
such as synaptojanin [42], diaphanous-related formin 1 
[43], the small GTPase RhoG [44] and CRN2 [45]. 
There is a strong correlation between elevated 
MMP levels, such as MMP-2 and MMP-9 and tumor cell 
invasiveness in glioma [46]. The fact that these ECM-
degrading enzymes are secreted from invadopodia [30] 
and our previous finding that RTVP-1 induces activation of 
MMP-2 [12] are in agreement with the current observation 
that RTVP-1 induces the formation of invadopodia and the 
degradation of ECM.
To further explore the molecular mechanism 
underlying the induction of glioma invasion by RTVP-1 
we performed a pull-down assay using His-tagged RTVP-
1 and glioma cell lysates followed by a mass spectrometry 
analysis and identified the key actin regulator N-WASP as a 
novel interacting protein of RTVP-1. We further validated 
this interaction using reciprocal co-immunoprecipitation 
and FRET analysis. We found that although the expression 
of N-WASP was not significantly increased in GBM 
specimens compared with normal brains, it was higher 
in glioma cell lines and GSCs as compared with human 
astrocytes and GSCs, respectively, similar to the results 
that were recently obtained for RTVP-1. 
Actin polymerization mediated by the N-WASP-
Arp2/3 pathway was shown to be involved in invadopodia 
formation in various cellular systems [30]. Moreover, the 
overexpression of deleted or mutant forms of the N-WASP 
activator, cortactin, that prevent the binding of specific 
partners such as Arp2/3 complex, F-actin or N-WASP, 
significantly decreases invadopodia formation and ECM 
degradation [47], showing that N-WASP is necessary for 
the invasion process. In gliomas it was recently shown that 
N-WASP is a key mediator of low oxygen-induced brain 
invasion [23].
Cell spreading is driven by actin nucleation 
machinery involving Arp2/3 complex [35], which is 
activated by the WASP protein family [36]. We therefore 
examined the effect of RTVP-1 and N-WASP on cell 
spreading. We found that overexpression of either 
N-WASP or RTVP-1 increased cell spreading while 
silencing of RTVP-1 inhibited this process. We further 
demonstrated the role of N-WASP in RTVP-1 effects 
by silencing the expression of N-WASP in RTVP-1 
overexpressing cells. A significant decrease in the effect 
of RTVP-1 on cell spreading, migration and ECM 
degradation was observed in N-WASP silenced cells, 
indicating that N-WASP is at least partially mediating 
RTVP-1 effects. 
Another interacting protein of RTVP-1 that 
was identified in the pull-down assay was hnRNPK. 
Heterogeneous nuclear ribonucleoproteins (hnRNPs) 
are a family of RNA binding proteins which have a 
central role in a variety of cellular processes including 
DNA repair, telomere biogenesis, cell signaling and the 
regulation of gene expression at both the transcriptional 
and translational levels [48]. hnRNPK is involved in cell 
spreading and is localized to structures called spreading 
initiation center (SIC) which are similar but distinct from 
the more mature focal adhesions. Indeed, inhibition of 
hnRNPK by antibodies increases cell spreading [37] and 
silencing of hnRNPK in differentiated N2A neuroblastoma 
cells increases the number and length of their neurites 
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[49]. Moreover, hnRNPK inhibits cell spreading and 
filopodia formation by a direct association with N-WASP 
[33]. We validated the interaction of hnRNPK and RTVP-
1 by co-immunoprecipitation and showed that hnRNPK 
was associated with N-WASP also in glioma cells. 
We found that hnRNPK was highly expressed 
in normal brain and its expression was decreased in 
astrocytic tumors in a tumor grade-dependent manner 
which is an inverse pattern to that of RTVP-1 [12]. 
Similarly, the expression of hnRNPK was the lowest in the 
mesenchymal GBM subtype, in contrast to the expression 
of RTVP-1. Overexpression of hnRNPK induced an 
inhibitory effect on cell spreading and migration of 
glioma cells whereas its silencing induced opposite 
effects. Thus, low levels of hnRNPK in glioma cells was 
associated with increased cell migration and invasion. 
Interestingly, the expression of hnRNPK is increased in 
a variety of tumors and in some studies hnRNPK was 
reported to promote tumor metastasis [50]. The reason for 
the differences in expression and functions of hnRNPK 
in different cell systems is not understood; however, 
the function of hnRNPK is dependent on its subcellular 
localization, i.e. cytoplasmic vs. nuclear [51, 52], and 
tyrosine phosphorylation [53] which may be cell-and 
tumor dependent. In a recent study it was shown that the 
nuclear level of hnRNPK is reduced in progressive murine 
fibrosarcoma compared to regressive tumors [54]. 
Based on the interaction of both RTVP-1 and 
hnRNPK with N-WASP and their opposite effects 
on glioma cell spreading, migration and invasion we 
speculated that RTVP-1 might compete with hnRNPK 
for the association with N-WASP. Indeed, overexpression 
of RTVP-1 decreased the association of N-WASP with 
hnRNPK suggesting that RTVP-1 may activate N-WASP 
by decreasing its inhibitory association with hnRNPK. 
Our conclusion was further validated by demonstrating 
that overexpression of RTVP-1 was able to abrogate the 
inhibitory effect of hnRNPK on N-WASP-induced glioma 
cell migration.
In summary, we report that RTVP-1 regulates 
glioma cell spreading, migration and invasion and that 
these effects are mediated via interaction with N-WASP 
and by interfering with the inhibitory effect of hnRNPK 
on the function of N-WASP. Thus, RTVP-1 is a potential 
therapeutic target for the inhibition of glioma cell and 
GSC migration and invasion.
MATERIALS AND METHODS
Materials
Antibodies for hnRNPK, His tag, N-WASP and 
cortactin were obtained from Santa Cruz (Santa-Cruz, 
CA). Oregon-green gelatin was purchased from Sigma 
Aldrich. Phalloidin-TRITC was obtained from Invitrogen 
(Carlsbad, CA).
Human tissue specimens
Frozen human non-tumor brain tissues and human 
GBM specimens were obtained from the Department of 
Neurosurgery at Henry Ford Hospital. All human materials 
were used in accordance with the policies of the Henry 
Ford Hospital institutional review board (IRB # 6399).
Cell cultures
The glioma cell lines A172, U251 and U87 were 
obtained from the American Type Culture Collection 
(Manassas, VA). Cells were maintained as previously 
described [55]. 
Generation of primary GSC cultures 
All human materials were used in accordance 
with the policies of the Henry Ford Hospital IRB. The 
generation, characterization and maintenance of GSCs 
were previously described [18, 27, 55, 56]. Briefly, fresh 
GBM specimens were processed and spheroids were 
maintained in neurosphere medium (DMEM-F12 1/1, 
supplemented with bFGF (20 ng/ml) and EGF (20 ng/
ml)). The GSCs were examined for self–renewal, neural 
differentiation and for their tumorigenic potential in nude 
mice. 
Transfection and transduction of glioma cells
Small interfering RNA (siRNA) duplexes were 
synthesized and purified by Dharmacon (Lafayette, CO). 
siRNA pools consisted of four siRNA duplexes for RTVP-
1, N-WASP or hnRNPK duplexes were employed. 
Transfection of glioma cells and GSCs HF2562 
and HF2609 with RTVP-1, N-WASP or hnRNPK siRNA 
duplexes (SMARTpool, Thermo Scientific, Lafayette, CO) 
was performed by siIMPORTER (Millipore, Billerica, 
MA) following the manufacturer’s recommendations. 
Lentivirus vectors (System Biosciences, Mountain 
View, CA) expressing RTVP-1 and shRNAs for RTVP-
1, N-WASP and hnRNPK were packaged and used to 
transduce the cells according to the manufacturer’s 
protocol. The medium was then replaced with fresh 
medium, and the cells were used 72 h post infection. For 
each experiments, we employed two different shRNA 
constructs that gave similar results.
The AdEasy system was kindly provided by Dr. 
Vogelstein (The Johns Hopkins University School of 
Medicine, Baltimore, MD) [57]. Adenoviruses expressing 
RTVP-1 were prepared as previously described [58]. 
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Cells were incubated with 5 multiplicity of infection of 
the recombinant adenovirus vectors for 1 h. The medium 
was then replaced with fresh medium and the cells were 
used 24 to 48 h post infection.
Transwell migration assay
Transwell chambers (BD Biosciences, San Jose, 
CA) were used according to the manufacturer’s protocol 
and as previously described [59]. Briefly, cells were 
harvested, resuspended in serum-free medium, and then 
transferred to the transwell chambers (25,000 cells per 
well). The chambers were then incubated for 3 h in culture 
medium with 10% FBS in the bottom chambers before 
analysis. The migrating cells on the lower surface were 
fixed and stained with 0.05% crystal violet and stained 
cells were counted under a microscope. Wound healing 
assay was done using culture-inserts purchased from 
Ibidi, LLC (Verona, WI) according to the manufacturer’s 
protocol.
In vitro invasion assay
Boyden chamber invasion assays were performed as 
previously described [12]. 
Cell spreading assay
Cells were trypsinized and incubated with gentle 
agitation in serum-free medium at 370c for 1 h. The cells 
were then plated on fibronectin-coated cover slips and 
allowed to spread for the indicated times (about 20 min). 
Multiple fields were imaged and spreading cells were 
defined as cells that were completely flattened and no 
longer had the white ring that is characteristic of floating 
cells.
Preparation of His tag RTVP-1 protein, Affinity 
pull-down assay and protein identification
Recombinant His-tagged RTVP-1 protein was 
produced and purified as described previously. After the 
washing process, the interacting proteins were eluted for 
analysis in-gel followed by mass spectrometry. Briefly, 
His-tagged RTVP-1 was immobilized on metal chelate 
(cobalt) agarose beads and then incubated with U87 cell 
lysates. The beads were then washed in washing buffer, 
and the bound proteins were eluted and size-fractioned by 
SDS/PAGE. Gels were stained with SimplyBlue SafeStain 
(Invitrogen) for band excision and mass spectrometry. 
Analysis of excised in-gel digested bands was carried 
out by using a LC-nano MS/MS spectrometer (NextGen 
Sciences, Ann Arbor, MI). The sequences of individual 
peptides were identified by using the Mascot algorithm to 
search and correlate the MS/MS spectra with amino acid 
sequences in the protein database.
Immunofluorescence staining and podosome 
formation
For immunofluorescence staining the cells 
were fixed in 4% paraformaldehyde for 20 min and 
permeabilized with wash solution (0.1% Triton X-100, 
1% bovine serum albumin in PBS) for 20 min. Cells were 
incubated with rabbit anti-cortactin polyclonal antibody 
(1:300) for 45 min, washed three times with PBS and 
incubated with Cy5 anti-rabbit antibody for 1 h. Coverslips 
were mounted on slides using anti-fade solution.
For the identification of podosomes, cells were 
incubated with rabbit anti-cortactin polyclonal antibody 
(1:300) for 45 min, washed three times with PBS and 
incubated with Cy5 anti-rabbit antibody for 1 h. For 
F-actin staining, cells were incubated with TRITC-
conjugated phalloidin (1:200) for 20 min. Coverslips 
were mounted on slides using anti-fade solution. For 
quantifying matrix degradation, images of 10 fields/10mm² 
per slide were acquired using eight-bit 512×512 pixel 
confocal Zeiss LSM510 microscope and AIM software. 
The percentage of degraded matrix per slide was analyzed 
using ImageJ software.
Extracellular matrix degradation assay
Fluorescently labeled fibronectin/gelatin-coated 
coverslips were prepared as described recently [55, 
60]. Briefly, coverslips were coated with Oregon green 
488-conjugated fibronectin/gelatin mixture (Sigma 
Chemical Co., St. Louis, MO) + 2% sucrose, cross-linked 
for 15 min in 0.5% glutaraldehyde in PBS, and incubated 
in 5 mg/ml NaBH4 in PBS for 3 min. After washing with 
DMEM at 37°C, cells were plated on coated coverslips in 
DMEM and incubated for 17 h. 
Western blot analysis
Western blot analysis was performed as described 
[61]. Equal loading was verified using an anti-β-actin 
antibody.
Real-time quantitative PCR analysis
Total RNA was extracted using RNeasy midi kit 
according to the manufacturer’s instructions (Qiagen, 
Valencia, CA). Reverse transcription reaction was 
carried out using 2 μg total RNA as described for the 
RT-PCR analysis. A primer optimization step was tested 
for each set of primers to determine the optimal primer 
concentrations. Once the optimal primer concentrations 
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were determined, primers, 25 μl of 2× SYBR Green 
Master Mix (Invitrogen, Carlsbad, CA), and 30 to 100 
ng cDNA samples were resuspended in a total volume 
of 50 μl PCR amplification solution. The following 
primers were used: hnRNPK forward, and S12 forward, 
TGCTGGAGGTGTAATGGACG; S12 reverse, 
CAAGCACACAAAGATGGGCT.
FRET analysis
FRET was measured by the donor-sensitized 
acceptor fluorescence technique. Three sets of filters were 
used, one optimized for donor fluorescence (Exc. 468 nm, 
Em. 475-505 nm), a second for acceptor fluorescence 
(Exc. 514 nm, Em. 530LP), and the third for FRET (Exc. 
468 nm, Em. 530LP). FRET was corrected as described 
below and the FRET efficiency was determined. To 
measure FRET, three images were acquired for each set 
of measurements: YFP excitation/YFP emission image 
(YFP channel); CFP excitation/CFP emission image 
(CFP channel); and CFP excitation/YFP emission image 
(FRET channel). The latter is a raw uncorrected FRET 
image, which contains two non-FRET components: (a) the 
bleed-through of the CFP emission into the YFP detection 
channel and (b) the cross-excitation of YFP by the CFP 
excitation laser.
To calculate and eliminate the non-FRET 
components, a set of reference images was acquired from 
single-labeled CFP- or YFP-expressing cells for each 
set of acquisition parameters used to obtain the FRET 
experimental images. Using a pixel-by-pixel comparison 
of the intensity values within the CFP channel images to 
the FRET channel images obtained from the CFP-only 
expressing cells, a calibration curve was derived, which 
expressed the level of CFP bleed-through into the FRET 
channel as a function of the CFP fluorescence in the CFP 
channel. Such curve was plotted for each set of acquisition 
parameters used in the FRET measurements.
Similarly, calibration curves expressing the level 
of YFP cross-excitation by the CFP excitation laser as 
a function of YFP fluorescence were derived using YFP 
channel and FRET channel images obtained from the 
YFP-only expressing cells. Subsequently, based on the 
pixel-by-pixel comparison of the FRET channel versus 
the CFP channel and the FRET channel versus the YFP 
channel, images were obtained from the double-labeled 
cells and using the calibration curves.
The non-FRET components were calculated and 
subtracted from each raw FRET image yielding corrected 
FRET images. The FRET efficiency was calculated on 
a pixel-by-pixel basis using the following equation: 
FRETeff=FRETcorr/(FRETcorr + CFP)x100%, where 
FRET corr is the pixel intensity in the corrected FRET 
image and CFP is the intensity of the corresponding pixel 
in the CFP channel image. To increase the reliability of the 
calculations and to prevent low-level noise from distorting 
the calculated ratio, pixels below 50 intensity units and 
saturated pixels were excluded from the calculations and 
their intensities were set to zero. 
Statistical analysis of TCGA data
The results are presented as the mean values ± SD. 
The data of patient specimens are presented graphically 
with median and interquartile range noted. Data were 
analyzed using analysis of variance or a Student’s t-test. 
Correlation was assessed with the Pearson’s correlation 
coefficient and tested against a correlation of zero 
(no correlation). The squared Pearson coefficient, or 
coefficient of determination (R2) for a single predictor 
regression, is given on the scatter plots. Kaplan-Meier 
analysis was used to produce survival curves with 
differences tested between groups by the log-rank test. 
Data were analyzed on a log 2 scale as appropriate.
Statistical analysis
The results are presented as the mean values ± SD. 
The data of patient specimens are presented graphically 
with median and interquartile range noted. Data were 
analyzed using analysis of variance or a Student’s t-test 
with correction for data sets with unequal variances. 
An age-adjusted t-test was taken from a linear model 
including age as a covariate. Correlation was assessed 
using Pearson’s correlation coefficient and tested against 
a correlation of zero (no correlation). The squared Pearson 
coefficient, or coefficient of determination (R2) for a single 
predictor regression, is given on the scatter plots. Kaplan-
Meier analysis was used to produce survival curves with 
differences tested between groups by the log-rank test. 
Data were analyzed on a log 2 scale as appropriate. 
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